Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization
4
Building a Low-Dose Radiation Therapy Program for Benign Disease
5